Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2207119 | 0.88 | KMT2A (0.58) | SMN1; SMN2KMT2AMAOBLMNAHPGD | |
| SCHEMBL29818763 | 0.88 | KMT2A (0.58) | SMN1; SMN2KMT2AMAOBLMNAHPGD | |
| SCHEMBL10477884 | 0.88 | KMT2A (0.53) | SMN1; SMN2KMT2AMAOBLMNAHPGD | |
| SCHEMBL7145799 | 0.88 | KMT2A (0.53) | SMN1; SMN2KMT2AMAOBLMNAHPGD | |
| SCHEMBL19850488 | 0.88 | SMN1; SMN2 (0.48) | SMN1; SMN2KMT2AMAOBLMNAHPGD | |
| SCHEMBL19871712 | 0.88 | SMN1; SMN2 (0.48) | SMN1; SMN2KMT2AMAOBLMNAHPGD | |
| SCHEMBL19850428 | 0.88 | SMN1; SMN2 (0.48) | SMN1; SMN2KMT2AMAOBLMNAHPGD | |
| Hydrochloric Acid SCHEMBL16030632 | 0.87 | KMT2A (0.56) | SMN1; SMN2KMT2AMAOBLMNAHPGD | |
| SCHEMBL12269320 | 0.86 | SMN1; SMN2 (0.47) | SMN1; SMN2KMT2AMAOBLMNAHPGD | |
| SCHEMBL3443080 | 0.86 | KMT2A (0.58) | SMN1; SMN2KMT2AMAOBLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-3194367-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3194367-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3194367-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | Boehringer Ingelheim International GmbH (DE) | 2017-07-26 | — | — | EP | disclosed |
| US-9340510-B2 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340510-B2 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340510-B2 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| WO-2016041845-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-24 | — | — | WO | disclosed |
| US-20160075657-A1 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-17 | — | — | US | disclosed |
| US-20160075657-A1 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-17 | — | — | US | disclosed |
| EP-0825189-B1 | 1,4-BENZODIOXIN DERIVATIVES | NISSHIN PHARMA INC (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-6130243-A | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DIABETES, HYPERGLYCEMIA AND OBESITY IN MAMMALS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 2000-10-10 | — | — | US | disclosed |
| EP-0825189-A1 | 1,4-BENZODIOXIN DERIVATIVES | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1998-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075657-A1 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | QDPR, RECQL, TPMT | SMN1; SMN2 3350/4885KMT2A 1979/4885MAOB 933/4885 |
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | SMN1; SMN2 1178/4885KMT2A 3722/4885MAOB 290/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | SMN1; SMN2 1178/4885KMT2A 3722/4885MAOB 290/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | SMN1; SMN2 1178/4885KMT2A 3722/4885MAOB 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.